Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EUDA Health Holdings (EUDA) Notes Payables (2021 - 2025)

EUDA Health Holdings (EUDA) has disclosed Notes Payables for 4 consecutive years, with $2.1 million as the latest value for Q4 2024.

  • Quarterly Notes Payables rose 178.25% to $2.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2024, up 178.25% year-over-year, with the annual reading at $2.1 million for FY2024, 178.25% up from the prior year.
  • Notes Payables for Q4 2024 was $2.1 million at EUDA Health Holdings, up from $759442.0 in the prior quarter.
  • The five-year high for Notes Payables was $2.1 million in Q4 2022, with the low at $205427.0 in Q4 2021.
  • Average Notes Payables over 4 years is $1.1 million, with a median of $759442.0 recorded in 2023.
  • The sharpest move saw Notes Payables surged 928.65% in 2022, then plummeted 64.06% in 2023.
  • Over 4 years, Notes Payables stood at $205427.0 in 2021, then soared by 928.65% to $2.1 million in 2022, then tumbled by 64.06% to $759442.0 in 2023, then soared by 178.25% to $2.1 million in 2024.
  • According to Business Quant data, Notes Payables over the past three periods came in at $2.1 million, $759442.0, and $320766.0 for Q4 2024, Q4 2023, and Q1 2023 respectively.